Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies

Leukemia and Lymphoma

Volumn 52, Issue 2, 2011, Pages 179-193

  Morrissey, C Orla ^a,b   Chen, Sharon C A ^c   Sorrell, Tania C ^d   Bradstock, Kenneth F ^e   Szer, Jeffrey ^f   Halliday, Catriona L ^c   Gilroy, Nicole M ^c   Schwarer, Anthony P ^g   Slavin, Monica A ^b,f  

^a ALFRED HOSPITAL   (Australia)

^b BURNET INSTITUTE   (Australia)

^c Centre for Infectious Diseases and Microbiology   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g BOX HILL HOSPITAL   (Australia)

Author keywords

Aspergillus; bias; clinical trial; Diagnostic tests; evaluation

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CASPOFUNGIN; CORTICOSTEROID; POSACONAZOLE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ASPERGILLUS; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEBRILE NEUTROPENIA; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RESOLUTION COMPUTED TOMOGRAPHY; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; INTERMETHOD COMPARISON; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SCREENING;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMATOLOGIC NEOPLASMS; HUMANS; MANNANS; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK FACTORS;

EID: 79551640723     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.542600     Document Type: Review

References (96)

1. Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005;43(Suppl. 1):49-58.
2. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006;91:1068-1075.
3. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007;44:531-540.
4. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infections in adult hematopoietic stem cell transplant recipients: analysis of a multicenter prospective antifungal therapy (PATH) alliance registry. Clin Infect Dis 2009;48:265-273.
5. Reichenberger F, Habicht J, Matt P, et al. Diagnostic yield of bronchoscopy in histologically proven invasive pulmonary aspergillosis. Bone Marrow Transplant 1999;24:1195-1199.
6. Jantunen E, Piilonen A, Volin L, et al. Diagnostic aspects of invasive Aspergillus infections in allogeneic BMT recipients. Bone Marrow Transplant 2000;25:867-871.
7. Wingard JR. Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2004;39(Suppl. 4):38-43.
8. Martino R, Viscoli C. Empirical antifungal therapy in patients with neutropenic and persistent or recurrent fever of unknown origin. Br J Haematol 2006;132:138-154.
9. Ben-Ami R, Lewis RE, Kontoyiannis DP. Invasive mold infections in the setting of hematopoietic cell transplantation: current trends and new challenges. Curr Opin Infect Dis 2009;22:376-384.
10. Verweij PE, Stynen D, Rijs AJ, de Pauw BE, Hoogkamp-Korstanje JA, Meis JF. Sandwich enzyme-linked immunosorbent assay compared with pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients. J Clin Microbiol 1995;33:1912-1914.
11. Bretagne S, Costa J-M, Bart-Delabesse E, Dhedin N, Rieux C, Cordonnier C. Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis. Clin Infect Dis 1998;26: 1407-1412.
12. Maertens J, Verhaegen J, Demuynck H, et al. Autopsycontrolled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at-risk for invasive aspergillosis. J Clin Microbiol 1999;37:3223-3228.
13. Kami M, Fukui T, Ogawa S, et al. Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin Infect Dis 2001;33:1504-1512.
14. Sulahian A, Boutboul F, Ribaud P, Lebalc T, Lacroix C, Derouin F. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer 2001;91:311-318.
15. Costa C, Costa J-M, Desterke C, Botterel F, Cordonnier C, Bretagne S. Real-time PCR coupled with automated DNA extraction and detection of galactomannan antigen in serum by enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis. J Clin Microbiol 2002;40:2224-2227.
16. Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002;20:1898-1906.
17. Maertens J, Van Eldere J, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts M. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002;186:1297-1306.
18. Pinel C, Fricker-Hidalgo H, Lebeau B, et al. Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J Clin Microbiol 2003;41:2184-2186.
19. Buchheidt D, Hummel M, Schleiermacher D, et al. Prospective clinical evaluation of a LightCyclerTM-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004;125:196-202.
20. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004;190: 641-649.
21. Rovira M, Jimenez M, Puig de la Bellacasa J, et al. Detection of Aspergillus galactomannan by enzyme immunoabsorbent assay in recipients of allogeneic hematopoietic stem cell transplantation: a prospective study. Transplantation 2004;77:1260-1264.
22. Einsele H, Hebart H, Roller G, et al. Detection and identification of fungal pathogens in blood by using probes. J Clin Microbiol 1997;35:1353-1360.
23. Skladny H, Buchheidt D, Baust C, et al. Specific detection of Aspergillus species in blood and bronchoalveolar lavage samples of immunocompromised patients by two-step PCR. J Clin Microbiol 1999;37:3865-3871.
24. Hebart H, Loffler J, Meisner C, et al. Early detection of Aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis 2000; 181:1713-1719.
25. Williamson EC, Leeming JP, Palmer HM, Steward CG, Warnock D. Diagnosis of invasive aspergillosis in bone marrow transplant recipients by polymerase chain reaction. Br J Haematol 2000;108:132-139.
26. Buchheidt D, Baust C, Skladny H, et al. Detection of Aspergillus species in blood and bronchoalveolar lavage samples from immunocompromised patients by means of 2- step polymerase chain reaction: clinical results. Clin Infect Dis 2001;33:428-435.
27. Lass-Flö rl C, Aigner J, Gunsilius E, et al. Screening for Aspergillus spp. using polymerase chain reaction of whole blood samples from patients with haematological malignancies. Br J Haematol 2001;113:180-184.
28. Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan and a (1!3)-b-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorder. J Clin Microbiol 2004;42:2733-2741.
29. Jordanides NE, Allan EK, McLintock LA, et al. A prospective study of real-time panfungal PCR for the early diagnosis of invasive fungal infection in haemato-oncology patients. Bone Marrow Transplant 2005;35:389-395.
30. Florent M, Katsahian S, Vekhoff A, et al. Prospective evaluation of a polymerase chain reaction-ELISA targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematological malignancies. J Infect Dis 2006;193:741-747.
31. Halliday C, Hoile R, Sorrell T, et al. Role of prospective screening of blood for invasive aspergillosis by polymerase chain reaction in febrile neutropenic recipients of haematopoietic stem cell transplant and patients with acute leukaemia. Br J Haematol 2006;132:478-486.
32. White PL, Linton CJ, Perry MD, Johnson EM, Barnes RA. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 2006;42:479-486.
33. Begg CB. Biases in the assessment of diagnostic tests. Stat Med 1987;6:411-423.
34. Reid MC, Lachs MS, Feinstein AR. Use of methodological standards in diagnostic test research: getting better but still not good. JAMA 1995;274:645-651.
35. Bogardus ST, Concato J, Feinstein AR. Clinical epidemiological quality in molecular genetic research: the need for methodological standards. JAMA 1999;281:1919-1926.
36. Lijmer JG, Mol BW, Heisterkamp S, et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999;282:1061-1066.
37. Marr KA, Leisenring W. Design issues in studies evaluating diagnostic tests for aspergillosis. Clin Infect Dis 2005; 41(Suppl. 6):381-386.
38. Guyatt GH, Tugwell PX, Feeny DH, Haynes RB, Drummond M. A framework for clinical evaluation of diagnostic technologies. CMAJ 1986;134:587-594.
39. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making 1991;11: 88-94.
40. Moons KGM, Grobbee DE. Diagnostic studies as multivariable, prediction research. J Epidemiol Comm Health 2002;56:337-338.
41. Moons KGM, Biesheuvel CJ, Grobbee DE. Test research versus diagnostic research. Clin Chem 2004;50:473-476.
42. Lord SJ, Irwig L, Simes RJ. When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test and when do we need randomised trials? Ann Intern Med 2006;144:850-855.
43. Bossuyt PM, Lijmer JG, Mol BW. Randomised comparisons of medical tests: some times invalid, not always efficient. Lancet 2000;356:1844-1847.
44. de Graaff JC, Ubbink DT, Tijssen JGP, Legemate DA. The diagnostic randomised clinical trial is the best solution for management issues in critical limb ischemia. J Clin Epidemiol 2004;57:1111-1118.
45. Severens JL, Donnelly JP, Meis JFGM, deVries Robbe PF, de Pauw BE, Verweij PE. Two strategies for managing invasive aspergillosis: a decision analysis. Clin Infect Dis 1997;25: 1148-1154.
46. Warnock DW. Fungal complication of transplantation: diagnosis, treatment and prevention. J Antimicrob Chemother 1995;36(Suppl. B):73-90.
47. Donnelly JP. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go. Clin Infect Dis 2006;42:487-489.
48. De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis - has the principle been proven? N Engl J Med 2007;356:409-411.
49. Maertens J, Theunissen K, Verbeken E, et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004; 126:852-860.
50. Wheat LJ. Rapid diagnosis of invasive aspergillosis by antigen detection. Transplant Infect Dis 2003;5:158-166.
51. Halliday C, Wu QX, James G, Sorrell T. Development of a nested qualitative real-time PCR assay to detect Aspergillus species DNA in clinical specimens. J Clin Microbiol 2005;43:5366-5368.
52. Slavin MA, Szer J, Grigg AP, et al. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mold infections. Intern Med J 2004;34:192-200.
53. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high-risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005;41:1242-1250.
54. Jennison C, Turnball BW. Two-sided tests: introduction. In: Jennison C, Turnball BW, editors. Group sequential methods with applications to clinical trials. Boca Raton, FL: Chapman & Hall/CRC; 2000. pp 21-48.
55. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mold infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-917. (Pubitemid 34229758)
56. Pocock SJ. The size of a clinical trial. In: Pocock SJ, editor. Clinical trials: a practical approach. Chichester, UK: Wiley Publications; 1983. pp 123-141.
57. Kirby A, Gebski VJ, Keech AC. Determining the sample size in a clinical trial. In: Keech A, Gebski V, Pike R, editors. Interpreting and reporting clinical trials. A guide to the CONSORT statement and the principles of randomized controlled trials. Sydney: Australian Medical Publishing Company; 2007. pp 28-36.
58. Bakhai A, Chhabra, Wang D. Endpoints. In: Wang D, Bakhai A, editors. Clinical trials: a practical guide to design, analysis and reporting. London: Remedica; 2006. pp 37-46.
59. Gebski VJ, Marschner I, Keech AC. Specifying objectives and outcomes for clinical trials. In: Keech A, Gebski V, Pike R, editors. Interpreting and reporting clinical trials. A guide to the CONSORT statement and the principles of randomized controlled trials. Sydney: Australian Medical Publishing Company; 2007. pp 21-26.
60. Hebart H, Klingspor L, Klingebiel T, et al. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. Bone Marrow Transplant 2009;43:553-561.
61. Barnes RA, White PL, Bygrave C, Evans N, Healy B, Kell J. Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. J Clin Pathol 2009;62:64-69.
62. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000;110:273-284.
63. McLintock LA, Jordanides NE, Allan EK, et al. The use of a risk group stratification in the management of invasive fungal infections: a prospective validation. Br J Haematol 2004;124: 403-404.
64. Klont RR, Meis JFGM, Verweij PE. Critical assessment of issues in the diagnosis of invasive aspergillosis. Clin Microbiol Infect 2001;7(Suppl. 2):32-37.
65. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. The interpretation of diagnostic data In: Sackett DL, Haynes RB, Guyatt GH, Tugwell P, editors. Clinical epidemiology: a basic science for clinical medicine. Toronto: Little, Brown and Company; 1991. pp 69-152.
66. Hope WW, Walsh TJ, Denning DW. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 2005;43(Suppl. 1):207-238.
67. Keech AC, Gebski V. Managing the resource demands of a large sample size in clinical trials: can you succeed with fewer subjects? In: Keech A, Gebski V, Pike R, editors. Interpreting and reporting clinical trials. A guide to the CONSORT statement and the principles of randomised controlled trials. Sydney: Australian Medical Publishing Company; 2007. Pp 39-45.
68. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100: 4358-4366.
69. Bradstock KF, Matthews JP, Lowenthal RM, et al. A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukaemia in first remission after induction therapy containing high-dose cytarabine. Blood 2005;105:481-488.
70. Becker MJ, Lugtenburg EJ, Cornelissen JJ, van der Schee C,Hoogensteden HC, De Marie S. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at-risk for invasive aspergillosis. Br J Haematol 2003;121:448-457.
71. Yoo J-H, Choi J-H, Choi S-M, et al. Application of nucleic acid sequence-based amplification for diagnosis of and monitoring the clinical course of invasive aspergillosis in patients with hematological diseases. Clin Infect Dis 2005; 40:392-398.
72. Millon L, Piarroux R, Deconinck E, et al. Use of real-time PCR to process the first galactomannan-positive serum sample in diagnosing invasive aspergillosis. J Clin Microbiol 2005;43: 5097-5101.
73. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004;4:349-357.
74. LatgéJ-P. The pathobiology of Aspergillus fumigatus. Trends Microbiol 2001;9:382-389.
75. Balloy V, Huerre M, LatgéJ-P, Chignard M. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 2005;73:494-503.
76. Berenguer J, Allende MC, Lee JW, et al. Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone- induced immunosuppression. Am J Respir Crit Care Med 1995;152:1079-1086.
77. Duong M, Ouellet N, Simard M, Bergeron Y, Olivier M, Bergeron MG. Kinetic study of host defense and inflammatory response to Aspergillus fumigatus in steroid-induced immunosuppressed mice. J Infect Dis 1998;178:1472-1482.
78. Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly JP. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis 2009;9:89-96.
79. Klingspor L, Loeffler J. Aspergillus PCR formidable challenges and progress. Med Mycol 2009;47(Suppl. 1):S241-S247.
80. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005;40:1762-1769.
81. Glasmacher A, Prentice A, Gorschlü ter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a metaanalysis of 3,597 patients. J Clin Oncol 2003;21:4615-4626.
82. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter randomized trial. Ann Intern Med 2003;138:705-713.
83. Grigg AP, Brown M, Roberts AW, Szer J, Slavin MA. A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host-disease at high-risk of invasive mold infections following allogeneic stem cell transplantation. Bone Marrow Transplant 2004;34:447-453.
84. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103: 1527-1533.
85. van Burik J-AH, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407-1416.
86. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006;42:1417-1427.
87. Bennett JE, Powers J, Walsh T. Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2003;36(Suppl. 3):117-122.
88. de Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infection Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-1821.
89. Nivoix Y, Fohrer C, Fornecker L, Herbrecht R. Clinical antifungal efficacy trials in invasive aspergillosis: consensus standards for trial design and room for improvement. Med Mycol 2006;44(Suppl. 1):289-294.
90. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764-771. (Pubitemid 29114295)
91. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fevers. N Engl J Med 2009;346:225-234.
92. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-1402.
93. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415. (Pubitemid 34851833)
94. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial). Clin Infect Dis 2007;44:1289-1297.
95. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-360.
96. Sargent D, Allegra C. Issues in clinical trial design for tumor marker studies. Semin Oncol 2002;29:222-230.